Kenalog

Triamcinolone Acetonide, the active ingredient in Kenalog, is a corticosteroid presented as a sterile injectable for intravenous use. It is employed to manage severe allergic reactions, acute asthma attacks, COPD exacerbations, rheumatic inflammatory disorders, and serious dermatologic conditions in patients requiring rapid anti‑inflammatory control.

GNH USA supplies Kenalog as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kenalog is a glucocorticoid that reduces inflammation and immune activity across several disease families.

- Severe allergic reactions: rapid suppression of airway and systemic inflammation. - Acute asthma exacerbations: improves airflow and reduces bronchial swelling. - COPD flare‑ups: decreases pulmonary inflammation and eases breathing difficulty. - Rheumatic and musculoskeletal inflammatory disorders: alleviates joint pain and swelling. - Severe dermatologic inflammatory conditions: controls skin inflammation and lesion formation.

Kenalog may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Hyperglycemia: elevated blood sugar levels. - Fluid retention: swelling of extremities. - Increased blood pressure. - Mood changes: anxiety or insomnia. - Gastrointestinal discomfort. - Skin thinning at injection sites.

Serious or Rare Side Effects: - Adrenal suppression: risk of insufficiency after abrupt discontinuation. - Severe infections: opportunistic bacterial, fungal or viral infections. - Osteonecrosis: bone tissue death, especially in weight‑bearing joints. - Visual disturbances: cataracts or glaucoma. - Anaphylaxis: life‑threatening allergic reaction. - Electrolyte imbalance: severe potassium loss.

Before initiating Kenalog therapy, clinicians should evaluate patient‑specific risk factors and monitor for complications.

- Assess infection risk: screen for active infections prior to use. - Monitor glucose: check blood sugar in diabetic patients. - Screen for hypertension: measure blood pressure regularly. - Consider bone health: limit duration in patients at risk for osteoporosis. - Avoid abrupt discontinuation: taper dose to prevent adrenal insufficiency. - Store at ambient temperature: keep in original container, protect from moisture and light.

Kenalog can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Systemic CYP3A4 inhibitors: may increase systemic exposure. - Live vaccines: reduced efficacy and increased infection risk. - Anticoagulants: heightened bleeding risk.

Moderate Interactions (Monitor Closely): - NSAIDs: additive gastrointestinal irritation. - Antidiabetic agents: may require dose adjustment of glucose‑lowering therapy.